Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MBX Biosciences, Inc. ( (MBX) ) has shared an announcement.
On March 9, 2026, MBX Biosciences reported that it had successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration on its once-weekly parathyroid hormone prodrug canvuparatide for chronic hypoparathyroidism. The FDA feedback enables MBX to finalize a Phase 3 program that is intended to support an eventual marketing application and potentially reposition the company as a leading player in hormone replacement for this rare disease.
The company plans to start a double-blind, placebo-controlled Phase 3 trial in the third quarter of 2026, enrolling about 160 patients in a 3:1 randomization to canvuparatide or placebo. The 26-week study will test whether patients can achieve normal serum calcium and independence from conventional calcium and vitamin D therapy, followed by an open-label extension to assess long-term safety and durability of effect.
MBX also disclosed that canvuparatide has received orphan drug designation from the European Medicines Agency for chronic hypoparathyroidism, complementing an existing U.S. orphan designation. The dual orphan status strengthens the candidate’s regulatory and commercial profile in a market the company estimates includes more than 250,000 patients across the U.S. and Europe, where current care does not address the underlying parathyroid hormone deficiency.
The most recent analyst rating on (MBX) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on MBX Biosciences, Inc. stock, see the MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Neutral.
The score is driven primarily by mixed fundamentals: strong capitalization and low leverage are outweighed by pre-revenue status, widening losses, and high cash burn. Technicals add support due to strong price trend and positive momentum, while valuation is a headwind given negative earnings and no dividend. Corporate updates are positive, highlighting pipeline progress and multi-year runway.
To see Spark’s full report on MBX stock, click here.
More about MBX Biosciences, Inc.
MBX Biosciences, Inc., based in Carmel, Ind., is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for endocrine and metabolic disorders. Its pipeline is led by canvuparatide for chronic hypoparathyroidism, alongside obesity candidates and imapextide for post-bariatric hypoglycemia, targeting large unmet needs and established regulatory pathways.
The company leverages its proprietary Precision Endocrine Peptide platform to design long-acting hormone replacement and metabolic therapies. By focusing on clinically validated targets and clearly defined endpoints, MBX aims to secure regulatory approvals and tap significant market opportunities in rare and chronic endocrine diseases.
Average Trading Volume: 713,461
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.37B
For a thorough assessment of MBX stock, go to TipRanks’ Stock Analysis page.